Home » Stocks » Aravive

Aravive, Inc. (ARAV)

Stock Price: $5.95 USD 0.12 (2.06%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $6.11 +0.16 (2.69%) Aug 13, 6:57 PM

Stock Price Chart

Key Info

Market Cap 95.31M
Revenue (ttm) n/a
Net Income (ttm) -26.31M
Shares Out 16.02M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $5.95
Previous Close $5.83
Change ($) 0.12
Change (%) 2.06%
Day's Open 5.82
Day's Range 5.62 - 6.10
Day's Volume 309,947
52-Week Range 3.34 - 15.62

More Stats

Market Cap 95.31M
Enterprise Value 41.81M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 16.02M
Float 9.67M
EPS (basic) -1.92
EPS (diluted) -1.92
FCF / Share -1.17
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 883,426
Short Ratio 4.39
Short % of Float 7.96%
Beta 3.20
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.57
Revenue n/a
Operating Income -28.20M
Net Income -26.31M
Free Cash Flow -18.57M
Net Cash 53.50M
Net Cash / Share 3.34
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -22.98%
ROE -46.84%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$27.75*
(366.39% upside)
Low
24.0
Current: $5.95
High
31.0
Target: 27.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue4.751.3740.00-----
Revenue Growth246.68%-96.57%------
Gross Profit4.751.3740.00-----
Operating Income-21.77-75.41-84.48-96.32-82.51-46.11-19.28-12.90
Net Income-18.22-76.33-84.98-95.82-82.18-57.51-18.50-13.22
Shares Outstanding11.597.175.875.134.833.150.080.02
Earnings Per Share-1.57-10.64-14.47-18.66-17.04-26.34-246.60-688.25
Operating Cash Flow-17.08-29.26-116-40.63-69.06-39.65-17.09-11.72
Capital Expenditures--0.03-4.30-0.09--0.83-0.01-
Free Cash Flow-17.08-29.29-121-40.72-69.06-40.48-17.10-11.72
Cash & Equivalents67.5659.3983.5320118217113.290.40
Total Debt10.23-5.43----4.46
Net Cash / Debt57.3259.3978.1020118217113.29-4.06
Assets82.1269.4793.7820618517414.682.19
Liabilities13.079.5311.0254.508.836.934.487.28
Book Value69.0559.9582.76151177167-47.29-34.74
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aravive, Inc.
Country United States
Employees 16
CEO Gail Frances McIntyre

Stock Information

Ticker Symbol ARAV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARAV
IPO Date March 21, 2014

Description

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.